University Of Alabama At Birmingham

SAN DIEGO — Etavopivat reduced the annualized vaso-occlusive crises rate vs. placebo for people with sickle cell disease, according to study data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — An investigational cell therapy reduced sickle hemoglobin and increased fetal and total hemoglobin for certain patients with sickle cell disease, according to results presented at ASH Annual Meeting and Exposition.

WASHINGTON — Children with lupus from areas of lower socioeconomic opportunity experience more severe disease complications and poorer outcomes than those from higher opportunity areas, according to data presented at ACR Convergence 2024.

SAN ANTONIO — Once-daily oral semaglutide conferred more weight loss vs. placebo plus lifestyle intervention and was similar vs. larger oral GLP-1 receptor agonist doses and weekly injectables for efficacy and safety, a speaker reported.

The risk for fractures among postmenopausal women may vary between ethnic origin groups, according to findings from the Women’s Health Initiative published in The Journal of Bone and Mineral Research.

Ten-year atherosclerotic CVD risk for people with stage 1 hypertension was substantially lower when estimated with the new PREVENT equations vs. the Pooled Cohort Equations, researchers reported.

Social determinants of health mediate the risk for treatment-resistant hypertension, especially among Black adults who may be disproportionately affected by barriers to equitable education and income, researchers reported.

Patients with active psoriatic arthritis who receive guselkumab demonstrate reduced work impairment, improved overall health and “substantial cost savings” through 2 years, according to data published in Rheumatology and Therapy.

After first-time stroke, comorbid PTSD was associated with increased risk for hospital readmission among Black veterans that was not observed among white veterans, researchers reported.

Black ICU patients with COVID-19 receiving high-dose inhaled nitric oxide had a decreased risk for 28-day and 90-day mortality, according to results published in American Journal of Respiratory and Critical Care Medicine.